+ Follow NOVARTIS PHARMA Tag
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 689454
[Title] => Reducing risk of MS disability progression
[Summary] => A new analysis demonstrated that fingolimod reduced the risk of disability progression in patients with relapsing-remitting multiple sclerosis (RRMS), regardless of treatment history.
[DatePublished] => 2011-05-26 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
)
)
NOVARTIS PHARMA
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 689454
[Title] => Reducing risk of MS disability progression
[Summary] => A new analysis demonstrated that fingolimod reduced the risk of disability progression in patients with relapsing-remitting multiple sclerosis (RRMS), regardless of treatment history.
[DatePublished] => 2011-05-26 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
)
)
abtest